Publication:
Efficacy of dexamethasone implants in uveitic macular edema in cases with behcet disease

dc.contributor.authorYalçınbayır, Özgür
dc.contributor.authorÇalışkan, Enver
dc.contributor.authorGündüz, Gamze Uçan
dc.contributor.authorGelişken, Öner
dc.contributor.authorKaderli, Berkant
dc.contributor.authorYücel, Ahmet Ali
dc.contributor.buuauthorYALÇINBAYIR, ÖZGÜR
dc.contributor.buuauthorÇalışkan, Enver
dc.contributor.buuauthorUÇAN GÜNDÜZ, GAMZE
dc.contributor.buuauthorYÜCEL, AHMET ALİ
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı
dc.contributor.researcheridJAC-9459-2023
dc.contributor.researcheridEQX-5743-2022
dc.contributor.researcheridAAH-6661-2021
dc.contributor.researcheridJYV-1141-2024
dc.date.accessioned2024-07-18T08:19:53Z
dc.date.available2024-07-18T08:19:53Z
dc.date.issued2019-01-01
dc.description.abstractPurpose: Investigation of the efficacy of intravitreal dexamethasone implants (0.7 mg) in patients with Behcet disease (BD) who had cystoid macular edema (CME) despite immunomodulatory treatment. Materials and Methods: Twenty-seven eyes of 20 patients who had intravitreal dexamethasone implant injections and follow-up for more than 6 months were included in this study. Best corrected visual acuities (BCVA), intraocular pressures (IOP), and central macular thicknesses (CMT) were recorded. Systemic immunomodulatory treatment was noted. Injection-related complications and the need for recurrent injections were recorded. Results: Statistically significant anatomical and functional success was achieved with a single injection. BCVA increased from 0.85 +/- 0.72 to 0.45 +/- 0.52 logMAR, while the mean CMT decreased from 406 +/- 190 to 243 +/- 101 mu m at the sixth month. The peak of visual acuity gain was reached within the first 2 months and a substantial proportion of the patients gained 3 or more lines. There was no complication other than transient IOP elevation in 4 eyes and cataract surgery in 2 eyes. Conclusion: Adjuvant intravitreal dexamethasone implant injections offer promising results in cases of BD with CME. It is effective in preserving the macular anatomy and vision particularly in transition to biological agents.
dc.identifier.doi10.1159/000490674
dc.identifier.eissn1423-0267
dc.identifier.endpage194
dc.identifier.issn0030-3755
dc.identifier.issue4
dc.identifier.startpage190
dc.identifier.urihttps://doi.org/10.1159/000490674
dc.identifier.urihttps://karger.com/oph/article/241/4/190/264076/Efficacy-of-Dexamethasone-Implants-in-Uveitic
dc.identifier.urihttps://hdl.handle.net/11452/43334
dc.identifier.volume241
dc.identifier.wos000466138500003
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherKarger
dc.relation.journalOphthalmologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectIntravitreal implant
dc.subjectPosterior uveitis
dc.subjectRisk
dc.subjectOutcomes
dc.subjectTherapy
dc.subjectAdjuvant
dc.subjectDexamethasone implant
dc.subjectCystoid macular edema
dc.subjectUveitis
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOphthalmology
dc.titleEfficacy of dexamethasone implants in uveitic macular edema in cases with behcet disease
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicatione21cc14e-0a29-42c8-a7a0-93bd3c780b36
relation.isAuthorOfPublicationfcd16549-6bb4-4c75-9919-689a032002f2
relation.isAuthorOfPublication34be4f44-59fb-4838-9179-a4b19b9575e6
relation.isAuthorOfPublication.latestForDiscoverye21cc14e-0a29-42c8-a7a0-93bd3c780b36

Files

Collections